2019 American Transplant Congress
Characterization Of Increased Risk Donor Post-transplant Viral Surveillance Protocol At A Comprehensive Transplant Center
University of Virginia Health System, Charlottesville, VA
*Purpose: With the growing opioid crisis, the number of deceased donors classified as Increased Risk Donor (IRD) has increased to nearly 20% nationally. The Organ…2019 American Transplant Congress
Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients
Chang-Gung Hospital, Taoyuan, Taiwan
*Purpose: Combination of anti-hepatitis B immunoglobulin and antiviral agents is the standard care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation. However,…2018 American Transplant Congress
Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis
BackgroundKidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus-induced liver cirrhosis (LC) remains controversial. This study compared outcomes of KT…2018 American Transplant Congress
Donor-Derived Hepatitis B Virus (HBV) Infection: Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: HBV can be transmitted from organ donor to recipient and is one of the viruses targeted by US Public Health Service increased risk (IR)…2018 American Transplant Congress
Evaluation of Hepatitis B Vaccination in Transplant Candidates
Background:Hepatitis B virus (HBV) vaccine series is recommended for all organ transplant candidates; high doses of vaccine are generally given to those with renal disease;…2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
1Auckland City Hospital, Auckland, New Zealand; 2Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…2018 American Transplant Congress
Impacts of HBsAg Seropositive Status on Patient and Graft Survival after Kidney Transplantation in the Era of New Antiviral Therapy: A Meta-Analysis
BACKGROUND: An association between HBsAg seropositive status and increased mortality after kidney transplantation has been demonstrated in previous studies over the past decade. Although chronic…2018 American Transplant Congress
Making Sense of Hepatitis B Reactivation Risk in Anti-HBc Antibody (Ab) Positive Liver Transplant Recipients
Background: Limited data exists regarding the rates of reactivation of hepatitis B virus (HBV) in anti-HBc Ab positive orthotopic liver transplant (OLT) recipients. Protocols vary…2018 American Transplant Congress
HIV, HBV, and HCV Screening with NAT and Serology in the OPO Setting
1UMass Memorial Medical Center, Worcester, MA; 2Northwestern University, Chicago, IL.
Background:In December 2014, the Organ Procurement & Transplantation Network updated policy to mandate screening with nucleic acid tests (NAT) for hepatitis C virus (HCV) in…
American Transplant Congress abstracts